510(k) Report

510(k) · Cleared

Cleared

Advia Immuno Modular System (Ims) B-Type Natriuretic Peptide (BNP) Assay

K051265510(k) TraditionalCleared Jun 13, 200528-day reviewClass II21 CFR 862.1117

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Bayer Healthcare, LLC · NBC Test, Natriuretic Peptide

Cleared on Jun 13, 2005 after a 28-day review. Our reading found no predicate number; beside “510(k)” the summary reads “KOSI7SOS5”, which our checks could not confirm as its predicate.

Decided
Jun 13, 2005
Review
28 days
Class
Class II
Product code
NBC
Recalls
None
Predicates
0

Our reading found no predicate number; beside “510(k)” the summary reads “KOSI7SOS5”, which our checks could not confirm as its predicate.

FIG. 1 — Lineage of K051265Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NBC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new NBC device

  1. #1 K262109 Access NT-proBNPscore 13.8 · 7 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—ADVIA Centaur BNP Assay
Named without a submission number
—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All NBC devices

NBC Test, Natriuretic Peptide: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · NBC

1in 2025

2007: 22008: 72010: 12020: 12021: 22022: 12023: 22024: 12025: 12026 (partial year): 4
2007high 7 (2008) · low 0 (2009)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NBC

126in 2008

2008: 126 days median2026 (partial year): 94 days median
2007high 126 (2008)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · NBC

1in 2020

2010: 12012: 22014: 12015: 12018: 12020: 1
2007high 2 (2012) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · NBC

17in 2025

2007: 172008: 152009: 352010: 612011: 532012: 232013: 132014: 702015: 432016: 312017: 92018: 72019: 92020: 62022: 42023: 262024: 142025: 17
2007high 70 (2014) · low 0 (2021)2025

MAUDE reports naming product code NBC, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—017
20087126015
20090—035
20101—161
20110—053
20120—223
20130—013
20140—170
20150—143
20160—031
20170—09
20180—17
20190—09
20201—16
20212—00
20221—04
20232—026
20241—014
20251—017
20264940—

What is it indicated for?

The Bayer ADVIA IMS BNP method is for in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA IMS® System. This assay is indicated for the measurement of plasma BNP as an aid in the diagnosis and assessment of the severity of heart failure. In patients with acute coronary syndromes (ACS), this test, in conjunction with other known risk factors, can also be used to predict survival as well as to predict the likelihood of future heart failure. This assay is not intended for use on any other system.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K051265: Advia Immuno Modular System (Ims) B-Type Natriuretic Peptide (BNP) Assay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K051265

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026